What's happened
On December 1-2, 2025, WHO issued its first guidelines recommending long-term use of GLP-1 drugs like Wegovy and Mounjaro for obesity treatment, recognizing obesity as a chronic disease. The US government finalized deals lowering prices for these drugs under Medicare and Medicaid, expanding coverage to more patients. Despite benefits, studies show weight and health gains reverse if treatment stops, highlighting need for ongoing care.
What's behind the headline?
WHO's Shift Recognizes Obesity as Chronic
The WHO's new guidelines mark a pivotal shift by officially classifying obesity as a chronic disease requiring lifelong management, not just lifestyle changes. This reframing legitimizes the use of GLP-1 drugs as part of comprehensive care, moving beyond stigma and simplistic views of willpower.
Access and Affordability Remain Major Barriers
Despite the endorsement, GLP-1 drugs remain costly and supply-constrained. The US government's recent pricing deals with Novo Nordisk and Eli Lilly reduce monthly costs for Medicare and Medicaid patients to around $245, with direct-to-consumer prices starting near $199-$350. However, experts warn these prices still exceed what many can afford, and global access is limited.
Long-Term Use is Essential but Challenging
Clinical data reveal that stopping GLP-1 treatment leads to significant weight regain and reversal of cardiovascular benefits, underscoring the need for ongoing therapy. This challenges patient expectations and healthcare systems to provide sustained support, including behavioral interventions and monitoring.
Impact on Food Industry and Society
Widespread GLP-1 use is already influencing dietary habits, with shifts toward higher-protein, nutrient-dense foods and smaller portion sizes. This could reshape food markets and public health trends but also raises questions about equitable access and long-term societal effects.
Political and Commercial Dynamics
The US administration's deals with pharmaceutical companies reflect a pragmatic approach to a public health crisis, balancing drug affordability with industry interests. The involvement of figures like President Trump and billionaire Mark Cuban highlights the complex interplay of politics, business, and health policy.
Future Outlook
Oral GLP-1 formulations like orforglipron promise greater convenience and potentially lower costs, broadening treatment options. However, the need for lifelong management, regulatory approvals, and equitable distribution remain critical challenges. Prevention efforts and environmental changes must continue alongside pharmacotherapy to address obesity comprehensively.
What the papers say
The Independent highlights WHO's call for fairer access to GLP-1 drugs and the economic burden of obesity, noting the drugs' addition to the essential medicines list and the need for long-term use. SBS News calls the WHO guideline "historic," emphasizing the recognition of obesity as a chronic disease and the explosion in GLP-1 use in Australia, while also noting concerns about long-term safety and the importance of prevention. Ars Technica and The Independent report on a JAMA Internal Medicine study showing weight regain and loss of health benefits after stopping tirzepatide, stressing the need for ongoing treatment. AP News and The Independent detail US government deals lowering GLP-1 drug prices for Medicare and Medicaid patients, with prices dropping from around $1,000 to $245 monthly, but experts caution affordability remains an issue. The New York Times explores the political dynamics, noting President Trump's shift from skepticism to promoting expanded access, while Business Insider UK discusses Mark Cuban's support for direct-to-consumer pricing models that bypass middlemen. SBS also examines how GLP-1 drugs are changing eating habits and the food industry. These diverse perspectives provide a comprehensive view of the medical, economic, political, and social dimensions of the GLP-1 obesity treatment landscape.
How we got here
Obesity affects over a billion people globally and is linked to serious health risks and economic costs. GLP-1 receptor agonists, initially for diabetes, have gained popularity for weight loss. High costs and limited access have restricted their use. In late 2025, WHO and US authorities moved to expand access and endorse long-term treatment, amid rising demand and new oral formulations in development.
Go deeper
- How do GLP-1 drugs work to treat obesity?
- What are the challenges in accessing these weight loss medications?
- What happens if patients stop taking GLP-1 drugs?
Common question
-
Why Are US Drug Prices Dropping for Weight-Loss Medications?
Recent changes in US healthcare policy have led to significant price cuts on popular weight-loss drugs like Wegovy and Ozempic. These reductions aim to make obesity treatments more accessible and improve public health outcomes. But what exactly prompted these price drops, and what do they mean for patients and the healthcare system? Below, we explore the key questions surrounding these changes and what they could mean for you.
-
How Will Lower Prices for Wegovy and Ozempic Impact Obesity and Public Health?
Recently, the US government announced significant price cuts for popular weight-loss drugs like Wegovy and Ozempic. This move aims to make these medications more accessible, especially for Medicare and Medicaid patients, and could have a major impact on obesity rates and public health. But what does this mean for individuals, healthcare costs, and long-term health? Below, we explore the key questions surrounding these changes and what they could mean for you.
-
How Will US Price Cuts on Weight-Loss Drugs Impact Obesity and Public Health?
In November 2025, the US government announced significant price reductions for popular weight-loss drugs like Wegovy and Ozempic. These changes aim to make obesity treatments more accessible and affordable, but what does this mean for public health, insurance coverage, and the risks involved? Below, we explore the key questions about these price cuts and their potential impact.
-
What Are the Biggest News Stories Today?
Stay updated with the top headlines shaping the world today. From US health policy changes to international conflicts, these stories are crucial for understanding current events. Curious about how these events connect or what they mean for you? Read on for clear, concise answers to your most pressing questions.
-
Are US drug price cuts making obesity treatments more affordable?
In December 2025, the US government announced significant price reductions for popular obesity drugs like Wegovy and Ozempic. This move aims to improve access to weight-loss medications, but what does it really mean for patients and public health? Below, we explore how these price cuts could impact affordability, coverage, and overall health outcomes, along with potential risks and societal effects.
-
What Does the WHO's New Guidance on Long-Term Obesity Drugs Mean for You?
Recently, the World Health Organization endorsed the long-term use of GLP-1 drugs like Wegovy and Mounjaro for obesity treatment, recognizing obesity as a chronic disease. This shift raises important questions about how these medications work, their safety, and how policies are changing to improve access. If you're curious about what this means for your health or for those struggling with obesity, read on to find clear answers to your most pressing questions.
More on these topics
-
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, with production facilities in nine countries and affiliates or offices in five. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owne
-
Donald John Trump is an American politician, media personality, and businessman who served as the 45th president of the United States from 2017 to 2021.
-
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Col. Eli Lilly, a
-
The World Health Organization is a specialized agency of the United Nations responsible for international public health. The WHO Constitution, which establishes the agency's governing structure and principles, states its main objective as "the attainment
-
Medicaid in the United States is a federal and state program that helps with medical costs for some people with limited income and resources.
-
Medicare is a government national health insurance program in the United States, begun in 1965 under the Social Security Administration and now administered by the Centers for Medicare and Medicaid Services.
-
Robert Francis Kennedy Jr. (born January 17, 1954), also known by his initials RFK Jr., is an American politician, environmental lawyer, author, conspiracy theorist, and anti-vaccine activist serving since 2025 as the 26th United States secretary of healt
-
Obesity is a medical condition, considered by multiple organizations to be a disease, in which excess body fat has accumulated to such an extent that it can have negative effects on health. People are classified as obese when their body mass index (BMI...
-
Tedros Adhanom Ghebreyesus is an Ethiopian biologist, public health researcher, and official who has been Director-General of the World Health Organization since 2017. Tedros is the first African in the role, and was endorsed by the African Union. He play
-
Semaglutide, sold under the brand name Ozempic among others, is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management.